Silence Therapeutics plc

Silence Therapeutics PLC

Biotechnology • Healthcare • London, United Kingdom • SLNCF (PNK)

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

44 20 3457 6900 72 Hammersmith Road, United Kingdom

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks - Yahoo Finance
Yahoo Finance • May 16
Frazier Life Sciences Management L.P. Decreases Holdings in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
MarketBeat • Dec 14
Silence Therapeutics (NASDAQ: SLN) CEO steps down; chairman becomes interim chief - Stock Titan
Stock Titan • Dec 15
Silence Therapeutics: Divesiran Targets High-Burden PV (NASDAQ:SLN) - Seeking Alpha
Seeking Alpha • Nov 18
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
Business Wire • Nov 6

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Silence Therapeutics plc had layoffs?
No layoff events have been recorded for Silence Therapeutics plc in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Silence Therapeutics plc have?
Silence Therapeutics plc has approximately 116 employees.
What industry is Silence Therapeutics plc in?
Silence Therapeutics plc operates in the Biotechnology industry, within the Healthcare sector.
Is Silence Therapeutics plc a publicly traded company?
Yes, Silence Therapeutics plc is publicly traded under the ticker symbol SLNCF on the PNK. The company has a market capitalization of approximately $0.28 billion.
Where is Silence Therapeutics plc headquartered?
Silence Therapeutics plc is headquartered in London, United Kingdom at 72 Hammersmith Road, United Kingdom.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.